Kaitlyn D’Onofrio

DocwireNews

<a href="https://www.docwirenews.com/docwire-pick/rheumatology-picks/dr-nowell-discusses-which-pros-are-most-important-to-rheumatology-patients/">Dr. Nowell Discusses Which PROs Are Most Important To Rheumatology Patients</a>In a video interview, Benjamin Nowell, Ph.D, Director of Patient-Centered Research, CreakyJoints, and principal investigator of ArthritisPower, <a href="https://www.docwirenews.com/docwire-pick/rheumatology-picks/dr-nowell-discusses-which-pros-are-most-important-to-rheumatology-patients/">discusses the results of a new study</a>, &ldquo;Which patient-reported outcomes do rheumatology patients find important to track digitally? A real-world longitudinal study in ArthritisPower,&rdquo; published in&nbsp;Arthritis Research &amp; Therapy. According to Dr. Nowell, two of the most important patient-reported outcomes (PROs) were fatigue and pain.One of the most interesting facets of this study is the number of clinical visits that took place: zero. &ldquo;I think what&rsquo;s also important to recognize about the study is that it shows the feasibility of conducting a longitudinal trial virtually with digital measures using a smartphone,&rdquo; Dr. Nowell explained. &ldquo;Everything was completed on [the] patient&rsquo;s smartphone. So, it just demonstrates that this kind of a study is possible to do, and possible to do over time.&rdquo;https://www.docwirenews.com/docwire-pick/rheumatology-picks/dr-nowell-discusses-which-pros-are-most-important-to-rheumatology-patients/<a href="https://www.docwirenews.com/docwire-pick/rheumatology-picks/adalimumab-biosimilar-arthritis-compare/">Adalimumab Versus Biosimilar: How Do These Drugs Compare in RA, PsA, PsO?</a>A analysis of two studies <a href="https://www.docwirenews.com/docwire-pick/rheumatology-picks/adalimumab-biosimilar-arthritis-compare/">comparing adalimumab biosimilar SDZ-ADL</a> versus reference adalimumab in PROs in patients with moderate&#8208;to&#8208;severe chronic plaque psoriasis, rheumatoid arthritis (RA), and psoriatic arthritis observed similar outcomes between the two treatments.https://www.docwirenews.com/docwire-pick/rheumatology-picks/adalimumab-biosimilar-arthritis-compare/<a href="https://www.docwirenews.com/docwire-pick/rheumatology-picks/arthritis-drug-tocilizumab-does-not-improve-mortality-in-severe-covid-19-pneumonia/">Arthritis Drug Tocilizumab Does Not Improve Mortality in Severe COVID-19 Pneumonia</a>The use of <a href="https://www.docwirenews.com/docwire-pick/rheumatology-picks/arthritis-drug-tocilizumab-does-not-improve-mortality-in-severe-covid-19-pneumonia/">tocilizumab</a> in patients hospitalized with severe COVID-19 pneumonia was not associated with improved mortality compared to placebo, a study found, but it may have helped improve secondary outcomes, including days on mechanical ventilation and length of stay. At day 28, mortality was similar between the tocilizumab and placebo groups, but the tocilizumab group had a higher median number of ventilator-free days, as well as a shorter median time to discharge or ready to be discharged and a shorter median ICU duration.https://www.docwirenews.com/docwire-pick/rheumatology-picks/arthritis-drug-tocilizumab-does-not-improve-mortality-in-severe-covid-19-pneumonia/<a href="https://www.docwirenews.com/docwire-pick/rheumatology-picks/risk-for-rheumatoid-arthritis-reduced-for-patients-with-t2dm/">Risk for Rheumatoid Arthritis Reduced for Patients With T2DM</a>Finally, patients with type 2 diabetes mellitus (T2DM) have a reduced risk for RA, which may be due to statin use, according to a <a href="https://academic.oup.com/rheumatology/advance-article/doi/10.1093/rheumatology/keab148/6137790">study</a>.https://www.docwirenews.com/docwire-pick/rheumatology-picks/risk-for-rheumatoid-arthritis-reduced-for-patients-with-t2dm/

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

Rheum Round-up: Dr. Nowell Discusses Most Important PROs for Rheumatology Pts, Adalimumab vs. Biosimilar, and more

Rheumatology

Dr. Nowell Discusses Which PROs Are Most Important To Rheumatology Patients ...

Rheum Round-up: Dr. Nowell Discusses Most Important PROs for Rheumatology Pts, Adalimumab vs.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe